Evidence map›Paper›PMID 21915633›Full record

ArticleJournal of clinical immunology2011

Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery.

Ausilia Sellitto, Gennaro Galizia, Umberto De Fanis, Eva Lieto, Anna Zamboli, Michele Orditura, Ferdinando De Vita, Riccardo Giunta, Giacomo Lucivero, Ciro Romano

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. T Regulatory CD4Medicina (Kaunas, Lithuania) · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ausilia SellittoDivision of Internal Medicine, Allergy and Clinical Immunology, Department of Medicine, Second University of Naples, Piazza Miraglia, 3, 80138, Naples, Italy.
Gennaro Galizia
Umberto De Fanis
Eva Lieto
Anna Zamboli
Michele Orditura
Ferdinando De Vita
Riccardo Giunta
Giacomo Lucivero
Ciro Romano

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD4+CD25+Foxp3+ regulatory T cells (Treg) specialize in suppressing immune responses. In this study, 47 consecutive colon cancer patients were subjected to circulating Treg frequency assessment by flow cytometry before and after cancer resection. Thirty-two healthy subjects served as controls. Circulating Treg frequencies were significantly higher in colon cancer patients with respect to healthy controls. When patients were subgrouped according to Dukes stages, a linear relationship was observed between Dukes stages and Treg frequencies. In radically resected patients, Treg frequencies were shown to have significantly dropped down. Patients with advanced colon cancer were more likely to have significantly higher proportions of circulating Treg frequencies than Dukes A and B patients when compared to healthy subjects. Of note, nonradically resected patients were found to display reductions in-but not normalization of-Treg frequencies. These results suggest that cancer itself may be able to drive Treg recruitment as a strategy of immunoevasion.

Indexed as

AdultAgedAged, 80 and overCarcinomaCD4 AntigensCell ProliferationCells, CulturedCell SeparationColonic NeoplasmsDisease ProgressionFemaleFlow CytometryHumansImmunosuppression TherapyInterleukin-2 Receptor alpha SubunitMaleCD4 AntigensInterleukin-2 Receptor alpha Subunit

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.